ScripThe big respiratory players will be casting envious glances at the launch of Verona Pharma’s chronic obstructive pulmonary disorder (COPD) drug, Ohtuvayre, which is going from strength to strength. Th
ScripJohnson & Johnson is aiming for the combination of Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) to become the preferred treatment for patients with first-line locally advanced or metasta
In VivoAs the pharmaceutical sector continues to evolve, the landscape of sales-driving indications is set to undergo transformation by 2030. In this article In Vivo delves into the therapeutic areas poise
ScripThe end of 2024 brought near-term cash shortfalls into focus at several biopharmaceutical companies, while others completed their assessments of potential alternatives to shutting their doors as capit